PURPOSE: To compare the mortality and causes of death in human immunodeficiency syndrome (HIV) patients with the background population. METHODS: All adult HIV patients treated in Danish HIV centers from 1995 to 2008 and 14 controls for each HIV patient were included. Age-adjusted mortality rates (MR) and mortality rate ratios (MRR) were estimated using direct standardization and Poisson regression analyses. Up to four contributory causes of death for each person were included in analyses of cause-specific MR. RESULTS: A total of 5,137 HIV patients and 71,918 controls were followed for 37,838 and 671,339 person-years (PY), respectively. Among non-injection drug use (IDU) HIV patients, the acquired immune deficiency syndrome (AIDS)-related MR/1,000 PY declined dramatically from 122.9 [95 % confidence interval (CI) 106.8-141.4] in 1995 to 5.0 (95 % CI 3.1-8.1) in 2008. The non-AIDS-related MR did not change substantially from 6.9 (95 % CI 3.8-12.5) to 5.6 (95 % CI 3.6-8.8). The MR of unnatural causes declined from 6.9 (95 % CI 3.8-12.5) to 2.7 (95 % CI 1.4-5.1). The MRR of infections declined from 46.6 (95 % CI 19.6-110.9) to 3.3 (95 % CI 1.6-6.6). The MRR of other natural causes of death remained constant. CONCLUSIONS: After the introduction of highly active antiretroviral therapy (HAART), the AIDS-related mortality has decreased substantially, but the long-term exposure to HIV and HAART has not translated into increasing mortality from malignancy, cardiovascular, and hepatic diseases.
PURPOSE: To compare the mortality and causes of death in human immunodeficiency syndrome (HIV) patients with the background population. METHODS: All adult HIVpatients treated in Danish HIV centers from 1995 to 2008 and 14 controls for each HIVpatient were included. Age-adjusted mortality rates (MR) and mortality rate ratios (MRR) were estimated using direct standardization and Poisson regression analyses. Up to four contributory causes of death for each person were included in analyses of cause-specific MR. RESULTS: A total of 5,137 HIVpatients and 71,918 controls were followed for 37,838 and 671,339 person-years (PY), respectively. Among non-injection drug use (IDU) HIVpatients, the acquired immune deficiency syndrome (AIDS)-related MR/1,000 PY declined dramatically from 122.9 [95 % confidence interval (CI) 106.8-141.4] in 1995 to 5.0 (95 % CI 3.1-8.1) in 2008. The non-AIDS-related MR did not change substantially from 6.9 (95 % CI 3.8-12.5) to 5.6 (95 % CI 3.6-8.8). The MR of unnatural causes declined from 6.9 (95 % CI 3.8-12.5) to 2.7 (95 % CI 1.4-5.1). The MRR of infections declined from 46.6 (95 % CI 19.6-110.9) to 3.3 (95 % CI 1.6-6.6). The MRR of other natural causes of death remained constant. CONCLUSIONS: After the introduction of highly active antiretroviral therapy (HAART), the AIDS-related mortality has decreased substantially, but the long-term exposure to HIV and HAART has not translated into increasing mortality from malignancy, cardiovascular, and hepatic diseases.
Authors: Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis Journal: N Engl J Med Date: 2003-02-20 Impact factor: 91.245
Authors: Sharon A Riddler; Xiuhong Li; James Otvos; Wendy Post; Frank Palella; Lawrence Kingsley; Barbara Visscher; Lisa P Jacobson; A R Sharrett Journal: J Acquir Immune Defic Syndr Date: 2008-07-01 Impact factor: 3.731
Authors: Line D Rasmussen; Lars H Omland; Court Pedersen; Jan Gerstoft; Gitte Kronborg; Janne Jensen; Niels Obel Journal: BMC Infect Dis Date: 2010-06-14 Impact factor: 3.090
Authors: Frederik N Engsig; Gitte Kronborg; Carsten S Larsen; Gitte Pedersen; Court Pedersen; Jan Gerstoft; Niels Obel Journal: BMC Cancer Date: 2011-06-25 Impact factor: 4.430
Authors: A Calcagno; S Nozza; C Muss; B M Celesia; F Carli; S Piconi; G V De Socio; A M Cattelan; G Orofino; D Ripamonti; A Riva; G Di Perri Journal: Infection Date: 2015-05-19 Impact factor: 3.553
Authors: M Platten; R Linnemann; T Kümmerle; N Jung; C Wyen; K Ehren; S Gravemann; D Gillor; O A Cornely; J Fischer; C Lehmann; J K Rockstroh; G Fätkenheuer; J J Vehreschild Journal: Infection Date: 2014-06-26 Impact factor: 3.553
Authors: K Ehren; C Hertenstein; T Kümmerle; J J Vehreschild; J Fischer; D Gillor; C Wyen; C Lehmann; O A Cornely; N Jung; S Gravemann; M Platten; J C Wasmuth; J K Rockstroh; C Boesecke; C Schwarze-Zander; G Fätkenheuer Journal: Infection Date: 2013-10-01 Impact factor: 3.553
Authors: Anoop S V Shah; Dominik Stelzle; Kuan Ken Lee; Eduard J Beck; Shirjel Alam; Sarah Clifford; Chris T Longenecker; Fiona Strachan; Shashwatee Bagchi; William Whiteley; Sanjay Rajagopalan; Shyamasundaran Kottilil; Harish Nair; David E Newby; David A McAllister; Nicholas L Mills Journal: Circulation Date: 2018-09-11 Impact factor: 29.690